Ignite Creation Date:
2024-05-06 @ 10:22 AM
Last Modification Date:
2024-10-26 @ 12:29 PM
Study NCT ID:
NCT03244657
Status:
UNKNOWN
Last Update Posted:
2017-08-09
First Post:
2017-08-07
Brief Title:
Phase IV Clinical Trial STAR Study Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy
Sponsor:
Chengdu Kanghong Biotech Co Ltd
Organization:
Chengdu Kanghong Biotech Co Ltd
Study Overview
Official Title:
Phase IV Clinical Trial STAR Study Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy
Status:
UNKNOWN
Status Verified Date:
2017-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore efficacy and safety of 05 mg conbercept ophthalmic injection for long-term treatment of polypoid choroidal vasculopathy PCV subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None